Monocyte-to-lymphocyte ratio in estimating the outcome of esophageal and gastric cancer treated with camrelizumab
Objective:To observe the impact of inflammatory biomarkers on the prognosis of patients with esophageal and gastric cancer treated with camrelizumab.Methods:The clinical data,together with the peripheral blood inflammatory biomarkers including neutrophil-to-lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR),monocyte-to-lymphocyte ratio(MLR)and systemic immune-inflammation index(SⅡ),were retrieved from the patients with esophageal and gastric cancer treated with camrelizumab in our hospital between July 2019 and January 2022.Then the relationship between these variables and the prognosis was analyzed in all patients.Results:Multivariate Cox regression analysis showed that higher MLR was adverse to the disease control in patients with upper gastrointestinal tumors and MLR≥O.515 was a risk factor for progression-free survival(PFS)and overall survival(OS)(P<0.05).Conclusion:MLR can be used as a predictive biomarker for the efficacy of upper gastrointestinal tumors treated with camrelizumab.